CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Orphan Medical, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Orphan Medical, Inc.
3180 PORTER DR
Phone: (302) 658-7581p:302 658-7581 PALO ALTO, CA  94304-1212  United States Ticker: ORPHORPH
This company is no longer actively traded on any major stock exchange.
Business Summary
Orphan Medical, Inc. acquires, develops and markets pharmaceutical products of high-medical value intended primarily to treat sleep disorders, pain and other central nervous system disorders that are addressed by physician specialists. As of December 31, 2004, the Company marketed three the United States Food and Drug Administration approved drugs. Xyrem (sodium oxybate) oral solution, the Company's lead product, is indicated for the treatment of cataplexy associated with narcolepsy. Antizol (fomepizole) Injection is an antidote for ethylene glycol and methanol ingestion in humans. Cystadane (betaine anhydrous for oral solution) is indicated for homocystinuria, a genetic disease. The Company's Antizol-Vet (fomepizole) for injection, an antidote for ethylene glycol ingestion in dogs, was approved using a new animal drug application. Orphan Medical is also assessing butamben (butyl-b-amino benzoate) as a treatment for intractable cancer pain.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/200512/31/2004YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer John H.Buillion

General Information
Number of Employees: 77 (As of 12/31/2004)
Outstanding Shares: 11,488,024 (As of 3/31/2005)
Shareholders: 3,000
Stock Exchange: NASD
Federal Tax Id: 411784594
Email Address: ir@orphan.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023